{"id":793361,"date":"2024-12-09T08:18:09","date_gmt":"2024-12-09T13:18:09","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/elevai-biosciences-a-subsidiary-of-elevai-labs-inc-announces-fda-regulatory-pathway-for-el-22-a-pioneering-obesity-therapy-targeting-fat-loss-and-muscle-preservation\/"},"modified":"2024-12-09T08:18:09","modified_gmt":"2024-12-09T13:18:09","slug":"elevai-biosciences-a-subsidiary-of-elevai-labs-inc-announces-fda-regulatory-pathway-for-el-22-a-pioneering-obesity-therapy-targeting-fat-loss-and-muscle-preservation","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/elevai-biosciences-a-subsidiary-of-elevai-labs-inc-announces-fda-regulatory-pathway-for-el-22-a-pioneering-obesity-therapy-targeting-fat-loss-and-muscle-preservation\/","title":{"rendered":"Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Announces FDA Regulatory Pathway for EL-22, a Pioneering Obesity Therapy Targeting Fat Loss and Muscle Preservation"},"content":{"rendered":"<div class=\"mw_release\">\n<ul type=\"disc\">\n<li style=\"margin-top:5pt;margin-bottom:5pt\">EL-22, a first-in-class myostatin asset, is being developed as a potential combination therapy with GLP-1 receptor agonists for obesity. It aims to address muscle loss, a common side effect of rapid weight loss from GLP-1-based treatments, by preserving muscle mass while reducing fat.<\/li>\n<li style=\"margin-top:5pt;margin-bottom:5pt\">The company plans to file an Investigational New Drug (\u201cIND\u201d) application with the U.S. Food and Drug Administration (\u201cFDA\u201d) in 2025.<\/li>\n<\/ul>\n<p>NEWPORT BEACH, Calif., Dec.  09, 2024  (GLOBE NEWSWIRE) &#8212; Elevai Labs Inc.\u00a0(Nasdaq: ELAB) (\u201cElevai\u201d or the \u201cCompany\u201d), a diversified holding company, subsidiary\u00a0Elevai Biosciences Inc. (\u201cElevai Biosciences\u201d), today announced the next steps in its regulatory strategy for EL-22, aimed at treating obesity and preserving muscle mass.<\/p>\n<p>In collaboration with KCRN Research, Inc., the Company is preparing for a pre-IND meeting with the FDA, anticipated in the first quarter of 2025. This meeting will establish the development pathway for EL-22, clarifying any additional preclinical requirements and adjustments to Chemistry, Manufacturing, and Controls before IND submission.<\/p>\n<p>EL-22 is an engineered probiotic designed to express myostatin on its surface, leveraging the myostatin pathway to support muscle health. Preclinical studies, including a 2022 study in mdx mice (a model of Duchenne muscular dystrophy), demonstrated significant physiological and functional improvements.<sup>1<\/sup> EL-22 has also completed a Phase 1 clinical trial in South Korea, where it was shown to be generally well tolerated and safe in healthy volunteers.<\/p>\n<p>\u201cRegulatory precedent for myostatin-based therapies in combination with GLP-1 receptor agonists are promising,\u201d said Deniel Mero, Co-founder of Elevai Biosciences. \u201cLeveraging existing data from our Korean licensing partner, including human safety studies, provides a strong foundation to accelerate the IND process and subsequent U.S. clinical trials. We are excited about EL-22\u2019s potential to redefine obesity care by combining effective weight loss with muscle preservation.\u201d<\/p>\n<p>Elevai aims to file the IND in 2025 and thereafter initiate clinical trials to evaluate the combination of EL-22 with GLP-1 receptor agonists for obesity treatment.<\/p>\n<p>\n        <strong>About Elevai Labs, Inc.<\/strong><br \/>\n        <br \/>Elevai Labs Inc. specializes in medical aesthetics and biopharmaceutical drug development, focusing on innovations for skin aesthetics and treatments tied to obesity and metabolic health. The Company operates a diverse portfolio of three wholly owned subsidiaries across the medical aesthetics and biopharmaceutical sectors, Elevai Skincare Inc., Elevai Biosciences Inc., and Elevai Research Inc. For more information please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=-g4NSBLyYvA6Yl5ZM6vK8kTBuAgxGe3qgzYN_VEkxREIQl-5qLpzdOPrdAJCWItrTpJDTeh9v_vEGjGoPCMujxJPyp5LTNn1wZRII6rFrmWTppczy0zHfzVHc0zpDGQtu7T2YC4Bof3Z1SxUQB6kjD1Om6MCYUDg1XqOoorXjNpatfGlO3rusCrAcVKzJtjPtQbG-uPuPdERqQqN83N5pqnbTrLUVBneldXpWRtbmTEQeQ5B3n8NLndV37KMHJ3gwaAnGAF-YFHY5A3--gJPrLZWhV_eW1PJSD3oB_RBjaEBXHv9gnn46sW4FYbF5rgwXsEJNzIJlBp3pbDliaGlPpQ4gnuGWDMuYt-efOYUUqrQ6nzrWw8Xq-XHHoVKyTcgNsBT8jNWGfdW7zaVojti6sni3gxoH9qIJTfDfQ_9Y7AsOsxFGR2LPMLmyeM9qD7_EeK_ZOSGlc48Y_9Lqwq1mn5xJc36pQ7uRxYTIiGfH6mAWgYe-CdJ-ul2mU-q7Mjg-7NA8NjEYGiOuLiNFb0Pwe9D24eBlZ0TTNPbTKe8mQ_Nlat-Weg0za2cSGmjzHMyfhci6wl6ptysBllAVfdHPHqM9uZwNtxGRqpQowgu11YWmBtGOP25DhpRcgPq9om59AIL5NNbhQKVa0Or7aGk2hX25zg8mnBNHTadcxkhstukUqHMK_uxv_QWvgRvYpVyiIU5ihvXyQy6FTLdU3tP1vhV5MTaMx5ADcQhNoKhVpX2SJLqpsql_KCxDbJxU00jtXy3UHITJzOGXAJhJYzNRDJEjcEukHKrgU_n5aMlAOe6xiGIdmyT_VBqeF-BUdJY-pcwO4nK5eJAdFZ6YwWWNn6hVMXtUk1SCf0BuJuxUUy_8aFiCcutPMTc_1g5UupwrlKzlQPz2Zo5Scb8QwuKXQ9dzQhSmpAM3OXGzsqgYFh0kVdM8Ea3A9k4NdOGry9JS8_dLZt8DuKRmNVCnkHOPjdOwB7utgjskgGUdkiS_ql9xDBH6yobAAUtAhOIv--qD2HCtjTHfpZ6Jes8ljuTIIZHFrq1RbCI_XtWRvYwfIb_bJ5bhznJD8b2egLiuPYWs2kQMoRnyvRwfdYkpyNEFisRsauOvQNli_3tTScvn1p4nEDaAL-No-dIM5-KeJ3q-VEpdfwPH43tarZfw25VtLL3FYR1hI_LzIaDlskPOd5-Cdvfrbu1TlWFWWbe8Oo-XQlR-gpfasTtKoHhxWo0FcNRHeYgjq-b1xd9qt3U6605Vy9pKl-Q5r4yk3mW_zik8us4TEfpZzUv5nrekc-7nLQIN4eQwFGKPjU0y0QtzXMnvZoCI3lYtt4RXtBSVmAPe3TPNkwhcvqg5zssYNajU5wKL_EfP6t0nzJpLTGXTqAY4LC59znO2sIzZVQGgHAx1Y1DCQjwLRESLhDQlh03KazHls9Dy5eAFl4VSoyMOfUFXtdFVrT5DQ1MlTfXwWQWzZskF4-i7iAJJaXRwLbUNeHwqSOq6JrWNg_qeHn7L1A9fx7ccr8XoeWciM8IHSOhc8EHoeYlKCTAvudkfPjAowlMJrGcayu3pK8MaBUVee-hrj3lB4k3U9NtRh5_Aguf0RF7locI85hB49p5AGXJQEmnGdUP5wukb9T-Cq4EiLIQgOq-xjWIe4if8wVAqmxXnKYf7SreWGTh_7URrvRlcg==\" rel=\"nofollow\" target=\"_blank\">www.elevailabs.com<\/a>.<\/p>\n<p>\n        <strong>About Elevai Biosciences<\/strong><br \/>\n        <br \/>Elevai Biosciences Inc., an Elevai Labs company, is a biopharmaceutical company focusing on the development and acquisition of cutting-edge aesthetic medicines. Our lead asset, EL-22, is leveraging an engineered probiotic approach to address obesity\u2019s pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists. For more information, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=-g4NSBLyYvA6Yl5ZM6vK8qUJPQnaYx7tSmbWxp7XE2ynnaLz8Rv6yP6m6wrZeDZSpiX1QF4_2VE4B_P94cMjByp342VepOo_Ovp0A0aE7R5q8uAfbysfvIeRoJe4rBtcFupxhfYVqFaaHmeUoMB9xq43euVQOudF1ctHAdlbQxLAtcFJ74X5Q-6sdVuZ1kv6VCo2xPAjU1a1FutHjJ7kXs4lJydf4ynEIhiWTRe-_ijM6mQVVtjZRghPHhbQzZTS4rQTYd7-iVjZdbmi0Mff5LNcDpAoLlUXUekna-kdbRyltElR2CyhWs85UIGM-yYXDN9y1oK65fbpSHPnnZuHmlyqqZ0_MOjhIRI1GlCO-uBYc464yQCqHvqBmADd18cYkCFB6ZoY7WsZuaBtSTImz0UamyswdogqTHN8JLTSR23LlTJ1m6XMPiLFK1o3DL1QA90r7riM7QMe9s4LId_rSUCVv4NVr_neJVwREWYplClL7FcHRl7hJduSr7ktrsIWRG6A-9uHSMOotQQHrggaJg05M2FIG1GHBUr13CnL_xOAtT7tBvDeY5XhvqNLyeihFh4jeL1t7HSiJogycPBgyHBY3mVGdrMYQqYQdddZRjoePtQOz1UXdQBEsrll7PQN7QV7lkm6slHZAJabba6eO4pmqN_3sPOL9qP13eN9ri0Gal2a1iRjJ4DBZYXB1urrIdqXuOBMQI3ywTH7ss9MCZExaHK4XFgQU8EYdkDXcWjn_PyPHISHaP-hKGTUnyuy3uBAGkr3hwgLvGo3ehf-6-z1oWsB-YjCbvsPGZyRZaPlyDALZouwHiU6faMJgmXtOmX1JX78wDROvw9390vqemvwWCOuBInT9EHEc8OKWlIE2pv6bX-5aJJSvsBU-I9CtiDS7f7LDrRjauafy5pUw932cmz1448O5pIbL_we-pDuKqJAcFCtPVJbrRyxSJPCJBS9lfgDz4szxuk0YxTS8hyoS9yvKnnzBbuLdo8T6LDUyEh9UqfCuTWEiF4wSx_Z55Zd-IUSwAYezwMfXEiKAuTdo0MGbKosGGdoZO_P2lFsfeMXUZLn3JYTjl320uq7E1ctUi4cVfa4mqcPnT72Cr7cy4-JjW5PQ_Q4OCK_yOyrK9W48m4ZPkOzWNBOLiK_DA_EjQsm20eIzcGwQU6hZP1qnbKhWblkUgxiBMXBANOq4tzIRuT0p-7YcGJ7-ZmHkuLnpu-kG_N3d9KOnafACq5dL93RGBrFgXF-LN8x-9Jlx_g7h6d6bJixgtGk7ZTIANCgTppF9mrMpOT3g5GvfE8vDUfDkIuha7Q9dzU0kLh8UzJcjmt4LYImUlrpB88LbdJexB3qB21Egk0H-PRO87dKPKSz786wozHHw9bCwiaHDs7hXZzxlyLSgwxOfwm9XDYKcjqaTEEDSSLvZiaqPUbY-d-mOqu4CyDk6ZRXzKWqhhFesfIf8AkdfT9Hwkio4BNLLS4gm5PFELa8YRBs1mkPSdTSD_2bKseg7GFrBqwgAQ73uacLycer4KqQU7gcGKvVUm9A5qGUf7WWmtjBra_IuQqfUuc92yV-HInljTOBx8or7NiO7CdcRqVsl04Nux7a957DXz0FTv5HyCOb7sxePMKEO7glcUOehaUKU7da2NPY2gfr9JbmpiJXn1-X\" rel=\"nofollow\" target=\"_blank\">www.elevaibio.com<\/a>.<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p>Statements contained in this press release regarding matters that are not historical facts are \u201cforward-looking statements\u201d within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as \u201cbelieves,\u201d \u201cexpects,\u201d \u201cplans,\u201d \u201cpotential,\u201d \u201cwould\u201d and \u201cfuture\u201d or similar expressions such as \u201clook forward\u201d are intended to identify forward-looking statements. Forward-looking statements are neither historical facts nor\u00a0assurances of future performance. Instead, they are based only on our current beliefs,\u00a0expectations\u00a0and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, activities of regulators and future regulations and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results. Therefore, you should not rely on any of these forward-looking statements. These risks and uncertainties include, among others: Elevai\u2019s limited operating history and historical losses; Elevai\u2019s ability to raise additional funding to complete the development and any commercialization of its product candidates; Elevai\u2019s dependence on the success of its product candidates EL-22 and EL-32; that Elevai may be delayed in initiating, enrolling or completing any clinical trials; competition from third parties that are developing products for similar uses; Elevai\u2019s ability to obtain, maintain and protect its intellectual property; Elevai\u2019s dependence on third parties in connection with manufacturing, clinical trials and preclinical studies; and Elevai\u2019s expectations regarding its growth, strategy, progress and the design, objectives and timing of its studies. These and other risks are described more fully in Elevai\u2019s filings with the Securities and Exchange Commission (\u201cSEC\u201d), including the \u201cRisk Factors\u201d section of the Company\u2019s Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on March 29, 2024, and its other documents subsequently filed with or furnished to the SEC. Investors and security holders are urged to read these documents free of charge on the SEC\u2019s web site at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=B_3HpvJK3OkJIpwWABkxrWj9Rf7-0UKq0utWk53uKIll5aYVaTu3Xlu-mZBUrTe99fbNs0nFJTl_abasvafCLe8iJQiErnEWaleEtz8pUEStpDwtCG0by3RMmD_FcdmT8SVuho-JpPXXki8eQ15XbR6yMQS-9MSfc7ImKArUH_BU4-ZqoQXo8KpTjJ-EoacHbiF-vlG8NffLjg5ObROxJ1B0wd01nRQpg9LLw-fRsVS0b2xPovz-oxA9EVIpbge_nIbXboKs0U9M8Lwr93F9AEfU5T8UTSQ2yAouXgh0j7KU5aXYZWzK5LTJiRfxhxVwVd_WvWdhYuowiLynLAFYNAu9P7ktdnXHMBzQnfZrR0QyG-yiTJAjklnLRquOK6jIQcre-iLT05DhSEzbaaidnBNhVMjuLsgdFWL6_QsbX4YjSE56MKUayOE9q66qj8Dm2AGgcsbR_m_dNNoDawSl9HX8k2CANm04CfQn6HtApDZuOrN5ZQ1E2jfMxst2pN5_ceqI9OA_wh7Hy_JVgsEZ6_g4jpDf-Q9xYdE1cHdIhnmbtALA44TjPGenOnPUxAXIaTFAk-8G_ZZ3faWlrRtZ7GU71ndBi_ogncbIwfMdHDvgTHxonHzAvlfxgTxum8Srd0JDbEuenE7B_cYqwSfUAB8eD6DKVnxd-xgAvopcrT8=\" rel=\"nofollow\" target=\"_blank\">www.sec.gov<\/a>. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.<\/p>\n<p>\n        <strong>IR Contact:<\/strong><br \/>\n        <br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ugl_TzmY8zGX5H1Gth1wOq23QKd1yGNhxJPcN7C_ZYK1TO2H6romGRWzSEPJxRc4xv_5N9vxb835IlSzFThFSXHhjVXNlnYbZqLKmSPk5x4=\" rel=\"nofollow\" target=\"_blank\">IR@ElevaiLabs.com<\/a>\n      <\/p>\n<p>\n        <sup>1<\/sup>\u00a0Reference: Sung DK, Kim H, Park SE, Lee J, Kim JA, Park YC, Jeon HB, Chang JW, Lee J. A New Method of Myostatin Inhibition in Mice via Oral Administration of\u00a0Lactobacillus casei\u00a0Expressing Modified Myostatin Protein, BLS-M22, Int. J. Mol. Sci.\u00a0<strong>2022<\/strong>, 23, 9059.\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=x4anSx5j6FfVNoLgwQgKkRYAIcwf4j0JbIpEIxtrSK-yyD9Y0NidEyHYDp3MLAVI8M1MUd1Pt9NKPgn4LTs9JGrVqHAt1Aqy8020meF3tuJhHV7MqFoyLydutoHFmJ25TbvM_xj54Llczem3H7K0h5Uh7zM3iaeYZWHOGVvB65S49a0GSSFrGOqCoBEdBKkA7SaFpKI8NF7AdKwkMFctbHPKD-daNhjE6-rsGMPlKC0GxFMq7LuVjVf2EFrHVfadQDn4XpvJCWQ8paPONG6OS51epDUc84b8CFIKXcMMY1S3EjOKAlpHLv8FdI8NhT_1AorUP97Wx4T7mLwanFg2uQ==\" rel=\"nofollow\" target=\"_blank\"><strong>https:\/\/doi.org\/10.3390\/ijms23169059<\/strong><\/a>.\u00a0<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxNjEyMSM2NjI4NTQ2IzIyNTg4MTI=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MjllZjdmM2ItOGU3OS00MTEwLThmZmItODE3NjhjNzNlYmI2LTEyNzAzNjE=\/tiny\/Elevai-Labs-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>EL-22, a first-in-class myostatin asset, is being developed as a potential combination therapy with GLP-1 receptor agonists for obesity. It aims to address muscle loss, a common side effect of rapid weight loss from GLP-1-based treatments, by preserving muscle mass while reducing fat. The company plans to file an Investigational New Drug (\u201cIND\u201d) application with the U.S. Food and Drug Administration (\u201cFDA\u201d) in 2025. NEWPORT BEACH, Calif., Dec. 09, 2024 (GLOBE NEWSWIRE) &#8212; Elevai Labs Inc.\u00a0(Nasdaq: ELAB) (\u201cElevai\u201d or the \u201cCompany\u201d), a diversified holding company, subsidiary\u00a0Elevai Biosciences Inc. (\u201cElevai Biosciences\u201d), today announced the next steps in its regulatory strategy for EL-22, aimed at treating obesity and preserving muscle mass. In collaboration with KCRN Research, Inc., the Company is preparing for &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/elevai-biosciences-a-subsidiary-of-elevai-labs-inc-announces-fda-regulatory-pathway-for-el-22-a-pioneering-obesity-therapy-targeting-fat-loss-and-muscle-preservation\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Announces FDA Regulatory Pathway for EL-22, a Pioneering Obesity Therapy Targeting Fat Loss and Muscle Preservation&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-793361","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Announces FDA Regulatory Pathway for EL-22, a Pioneering Obesity Therapy Targeting Fat Loss and Muscle Preservation - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/elevai-biosciences-a-subsidiary-of-elevai-labs-inc-announces-fda-regulatory-pathway-for-el-22-a-pioneering-obesity-therapy-targeting-fat-loss-and-muscle-preservation\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Announces FDA Regulatory Pathway for EL-22, a Pioneering Obesity Therapy Targeting Fat Loss and Muscle Preservation - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"EL-22, a first-in-class myostatin asset, is being developed as a potential combination therapy with GLP-1 receptor agonists for obesity. It aims to address muscle loss, a common side effect of rapid weight loss from GLP-1-based treatments, by preserving muscle mass while reducing fat. The company plans to file an Investigational New Drug (\u201cIND\u201d) application with the U.S. Food and Drug Administration (\u201cFDA\u201d) in 2025. NEWPORT BEACH, Calif., Dec. 09, 2024 (GLOBE NEWSWIRE) &#8212; Elevai Labs Inc.\u00a0(Nasdaq: ELAB) (\u201cElevai\u201d or the \u201cCompany\u201d), a diversified holding company, subsidiary\u00a0Elevai Biosciences Inc. (\u201cElevai Biosciences\u201d), today announced the next steps in its regulatory strategy for EL-22, aimed at treating obesity and preserving muscle mass. In collaboration with KCRN Research, Inc., the Company is preparing for &hellip; Continue reading &quot;Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Announces FDA Regulatory Pathway for EL-22, a Pioneering Obesity Therapy Targeting Fat Loss and Muscle Preservation&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/elevai-biosciences-a-subsidiary-of-elevai-labs-inc-announces-fda-regulatory-pathway-for-el-22-a-pioneering-obesity-therapy-targeting-fat-loss-and-muscle-preservation\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2024-12-09T13:18:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxNjEyMSM2NjI4NTQ2IzIyNTg4MTI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/elevai-biosciences-a-subsidiary-of-elevai-labs-inc-announces-fda-regulatory-pathway-for-el-22-a-pioneering-obesity-therapy-targeting-fat-loss-and-muscle-preservation\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/elevai-biosciences-a-subsidiary-of-elevai-labs-inc-announces-fda-regulatory-pathway-for-el-22-a-pioneering-obesity-therapy-targeting-fat-loss-and-muscle-preservation\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Announces FDA Regulatory Pathway for EL-22, a Pioneering Obesity Therapy Targeting Fat Loss and Muscle Preservation\",\"datePublished\":\"2024-12-09T13:18:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/elevai-biosciences-a-subsidiary-of-elevai-labs-inc-announces-fda-regulatory-pathway-for-el-22-a-pioneering-obesity-therapy-targeting-fat-loss-and-muscle-preservation\\\/\"},\"wordCount\":947,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/elevai-biosciences-a-subsidiary-of-elevai-labs-inc-announces-fda-regulatory-pathway-for-el-22-a-pioneering-obesity-therapy-targeting-fat-loss-and-muscle-preservation\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMxNjEyMSM2NjI4NTQ2IzIyNTg4MTI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/elevai-biosciences-a-subsidiary-of-elevai-labs-inc-announces-fda-regulatory-pathway-for-el-22-a-pioneering-obesity-therapy-targeting-fat-loss-and-muscle-preservation\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/elevai-biosciences-a-subsidiary-of-elevai-labs-inc-announces-fda-regulatory-pathway-for-el-22-a-pioneering-obesity-therapy-targeting-fat-loss-and-muscle-preservation\\\/\",\"name\":\"Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Announces FDA Regulatory Pathway for EL-22, a Pioneering Obesity Therapy Targeting Fat Loss and Muscle Preservation - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/elevai-biosciences-a-subsidiary-of-elevai-labs-inc-announces-fda-regulatory-pathway-for-el-22-a-pioneering-obesity-therapy-targeting-fat-loss-and-muscle-preservation\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/elevai-biosciences-a-subsidiary-of-elevai-labs-inc-announces-fda-regulatory-pathway-for-el-22-a-pioneering-obesity-therapy-targeting-fat-loss-and-muscle-preservation\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMxNjEyMSM2NjI4NTQ2IzIyNTg4MTI=\",\"datePublished\":\"2024-12-09T13:18:09+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/elevai-biosciences-a-subsidiary-of-elevai-labs-inc-announces-fda-regulatory-pathway-for-el-22-a-pioneering-obesity-therapy-targeting-fat-loss-and-muscle-preservation\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/elevai-biosciences-a-subsidiary-of-elevai-labs-inc-announces-fda-regulatory-pathway-for-el-22-a-pioneering-obesity-therapy-targeting-fat-loss-and-muscle-preservation\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/elevai-biosciences-a-subsidiary-of-elevai-labs-inc-announces-fda-regulatory-pathway-for-el-22-a-pioneering-obesity-therapy-targeting-fat-loss-and-muscle-preservation\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMxNjEyMSM2NjI4NTQ2IzIyNTg4MTI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMxNjEyMSM2NjI4NTQ2IzIyNTg4MTI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/elevai-biosciences-a-subsidiary-of-elevai-labs-inc-announces-fda-regulatory-pathway-for-el-22-a-pioneering-obesity-therapy-targeting-fat-loss-and-muscle-preservation\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Announces FDA Regulatory Pathway for EL-22, a Pioneering Obesity Therapy Targeting Fat Loss and Muscle Preservation\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Announces FDA Regulatory Pathway for EL-22, a Pioneering Obesity Therapy Targeting Fat Loss and Muscle Preservation - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/elevai-biosciences-a-subsidiary-of-elevai-labs-inc-announces-fda-regulatory-pathway-for-el-22-a-pioneering-obesity-therapy-targeting-fat-loss-and-muscle-preservation\/","og_locale":"en_US","og_type":"article","og_title":"Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Announces FDA Regulatory Pathway for EL-22, a Pioneering Obesity Therapy Targeting Fat Loss and Muscle Preservation - Market Newsdesk","og_description":"EL-22, a first-in-class myostatin asset, is being developed as a potential combination therapy with GLP-1 receptor agonists for obesity. It aims to address muscle loss, a common side effect of rapid weight loss from GLP-1-based treatments, by preserving muscle mass while reducing fat. The company plans to file an Investigational New Drug (\u201cIND\u201d) application with the U.S. Food and Drug Administration (\u201cFDA\u201d) in 2025. NEWPORT BEACH, Calif., Dec. 09, 2024 (GLOBE NEWSWIRE) &#8212; Elevai Labs Inc.\u00a0(Nasdaq: ELAB) (\u201cElevai\u201d or the \u201cCompany\u201d), a diversified holding company, subsidiary\u00a0Elevai Biosciences Inc. (\u201cElevai Biosciences\u201d), today announced the next steps in its regulatory strategy for EL-22, aimed at treating obesity and preserving muscle mass. In collaboration with KCRN Research, Inc., the Company is preparing for &hellip; Continue reading \"Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Announces FDA Regulatory Pathway for EL-22, a Pioneering Obesity Therapy Targeting Fat Loss and Muscle Preservation\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/elevai-biosciences-a-subsidiary-of-elevai-labs-inc-announces-fda-regulatory-pathway-for-el-22-a-pioneering-obesity-therapy-targeting-fat-loss-and-muscle-preservation\/","og_site_name":"Market Newsdesk","article_published_time":"2024-12-09T13:18:09+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxNjEyMSM2NjI4NTQ2IzIyNTg4MTI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/elevai-biosciences-a-subsidiary-of-elevai-labs-inc-announces-fda-regulatory-pathway-for-el-22-a-pioneering-obesity-therapy-targeting-fat-loss-and-muscle-preservation\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/elevai-biosciences-a-subsidiary-of-elevai-labs-inc-announces-fda-regulatory-pathway-for-el-22-a-pioneering-obesity-therapy-targeting-fat-loss-and-muscle-preservation\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Announces FDA Regulatory Pathway for EL-22, a Pioneering Obesity Therapy Targeting Fat Loss and Muscle Preservation","datePublished":"2024-12-09T13:18:09+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/elevai-biosciences-a-subsidiary-of-elevai-labs-inc-announces-fda-regulatory-pathway-for-el-22-a-pioneering-obesity-therapy-targeting-fat-loss-and-muscle-preservation\/"},"wordCount":947,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/elevai-biosciences-a-subsidiary-of-elevai-labs-inc-announces-fda-regulatory-pathway-for-el-22-a-pioneering-obesity-therapy-targeting-fat-loss-and-muscle-preservation\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxNjEyMSM2NjI4NTQ2IzIyNTg4MTI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/elevai-biosciences-a-subsidiary-of-elevai-labs-inc-announces-fda-regulatory-pathway-for-el-22-a-pioneering-obesity-therapy-targeting-fat-loss-and-muscle-preservation\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/elevai-biosciences-a-subsidiary-of-elevai-labs-inc-announces-fda-regulatory-pathway-for-el-22-a-pioneering-obesity-therapy-targeting-fat-loss-and-muscle-preservation\/","name":"Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Announces FDA Regulatory Pathway for EL-22, a Pioneering Obesity Therapy Targeting Fat Loss and Muscle Preservation - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/elevai-biosciences-a-subsidiary-of-elevai-labs-inc-announces-fda-regulatory-pathway-for-el-22-a-pioneering-obesity-therapy-targeting-fat-loss-and-muscle-preservation\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/elevai-biosciences-a-subsidiary-of-elevai-labs-inc-announces-fda-regulatory-pathway-for-el-22-a-pioneering-obesity-therapy-targeting-fat-loss-and-muscle-preservation\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxNjEyMSM2NjI4NTQ2IzIyNTg4MTI=","datePublished":"2024-12-09T13:18:09+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/elevai-biosciences-a-subsidiary-of-elevai-labs-inc-announces-fda-regulatory-pathway-for-el-22-a-pioneering-obesity-therapy-targeting-fat-loss-and-muscle-preservation\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/elevai-biosciences-a-subsidiary-of-elevai-labs-inc-announces-fda-regulatory-pathway-for-el-22-a-pioneering-obesity-therapy-targeting-fat-loss-and-muscle-preservation\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/elevai-biosciences-a-subsidiary-of-elevai-labs-inc-announces-fda-regulatory-pathway-for-el-22-a-pioneering-obesity-therapy-targeting-fat-loss-and-muscle-preservation\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxNjEyMSM2NjI4NTQ2IzIyNTg4MTI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxNjEyMSM2NjI4NTQ2IzIyNTg4MTI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/elevai-biosciences-a-subsidiary-of-elevai-labs-inc-announces-fda-regulatory-pathway-for-el-22-a-pioneering-obesity-therapy-targeting-fat-loss-and-muscle-preservation\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Announces FDA Regulatory Pathway for EL-22, a Pioneering Obesity Therapy Targeting Fat Loss and Muscle Preservation"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/793361","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=793361"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/793361\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=793361"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=793361"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=793361"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}